Member Info for The.Italian

morning all.i just said to mrs italian that i would have a quick check to see how the erp team was getting on with the circular and the first word i saw was"delay".this is all so horribly predictable.now it probably doesn't matter at all if there is some delay,but it's symptomatic of a level of ineptitude. i can appreciate the complexities of this situation,but why could they not build in some sort of time buttress to the proposed timescale.having to continually report days just serves to reinforce poor investor sentiment. if this were a one off,no one would comment,but its not.probaly easier to make money by betting on their inability to keep to a timescale than investing in the company.more time now for the s/p to erode before the issue.it's not going to go well unless they can and will announce some positive news.

interested to see if they get the circular out by tomorrow, or will it b delayed?

not good news for themhttps://www.cnbc.com/2022/10/14/beyond-meat-to-cut-19percent-of-its-workforce-as-sales-stock-struggle.html

afternoon albert.yes, thought it was a confident and informative performance.no manic eye rolling for him! lol .the distinction he drew between the napster vision and spotify and deezer was,as you say, quite revealing.looks like napster is aiming be very much its own man with a unique offering. let us hope we are able to participate,albeit probably in a very small way, in the journey.

https://www.youtube.com/watch?v=MI13dW3F3KE doesn't really add a great deal,but interesting see the CEO.he gets better after the first few minutes(imo) as he settles into the presentation.

came across this on another site.looks like its new today,but apologies if it has already been postedhttps://www.theguardian.com/business/2022/oct/14/lipstick-effect-britons--luxuries-cost-of-living-crisis

very interesting and quite encouraging over the medium term imo.

beechhurst,this is why,imo, one needs to be circumspect to a degree in one's expectations of sales.there are other products out there. of course, we may (and i hope we are) be able to leverage our advantage for those contraindicated for viagra and viagra type drugs, but until actual sales figures materialise we are in unknown territory.just my opinion of course.

well i did wonder bignose,seeing the 2x10k trades shortly before close!lol

yes it"s really very positive.nice to have a bit of positive coverage for a change.

notrac, a perfectly valid point. i am expecting probably two spikes.first on news of product launch.i expect that to be a fairly modest spike,as we know it is coming,although not when and until there is information about actual sales,its impact may be limited.second, .i expect a more substantial spike on FDA approval .fda approval is always seen as the "holy grail" for this type of product, but the question after approval will still be "how we;ll will it sell in practice"

i seem to recall some posters referring to a necessary lead in time before the umbro launch, such that vrs would need to be supplying the product some time ahead of the launch date.this makes sense to me ,although i know nothing about clothing supply chains etc.

two reasons for the apparent paradox imo.first the deal announcements were very light on detail.this is not unusual and probably largely to be expected because of the ostensible need to preserve confidentiality.unfortunately it can frequently be interpreted as suggesting the deals are not necessarily on great commercial terms. second,as i posted a few days ago, the jury will be out on how commercially viable the product is until some actual sales figures.need to be wary of over optimistic expectations in the absence of any actual figures.only my opinion of course.

https://www.linkedin.com/pulse/blood-age-clocks-can-revolutionise-insurance-process-deepankar-nayak by our very own Deep.at least it's sign of some activity by the coo!

morning bignose.well that was the inference i drew from the relative speed of ERP's response. bearing in mind the first review took 3 weeks, it seems reasonable to expect the second one, with less to review, should be completed in next few days , so hopefully the trial website will update soon. agree its possible they may have to wait until the rights issue is completed before starting p3 (quite likely really i suppose), but i think they will have to make the position clear in the prospectus.they will have to explain what the monies raised will be used for i assume ,so some reference to whatever is the position at that point re the p3 must surely be necessary?could be wrong of course and i do agree that they would probably prefer to say as little as possible till the issue is away. as always time will tell.

JR87 i expect we all harbour similar concerns.the cash raise was something we were all expecting (absent a significant upfront payment from a us partner, which was always a fairly vain hope) in some form or another. the only slight consolation i can take personally from this development is the mellon has felt it better to commit further funds rather than simply letting it go to the wall, which it would almost certainly do if he didn't help out.we can only speculate as to his reasons for adding to his investment here and it is not a given that this is done out of an expectation of a positive outcome at the end of the day (there are other possible reasons); but that is one possibility and i remain hopeful that this is indeed the reason and that it proves correct. just my view of course.

morning bignose.interesting posts re the current state of FDA application. I've looked at the QC comments and there seem a lot,bit I've no idea if this is anything to worry about or not.looking on the positive side ,ERP replied fairly quickly(less than a month)which may indicate that the queries were mostly formattingor presentational in nature, although some of them look a bit more substantial.anyway agree that the type c meeting seems some way off. agree that they may prefer not to have to announce any news until after the right issue is away,so delays may not be unwelcome from that perspective.disappointing news for us of course.need to keep an eye on trial site for updates.

https://3dprint.com/294819/construction-giant-holcim-invests-in-concrete-3d-printing-leader-cobod/ not sure what the implications,if any,are for VRS,but interesting.

personally i 5hink we have moved from a largely regulatory risk scenario to an execution risk one. i am fairly confident that FDA approval will be gained.the trial results were very good.there have been no real concerns on safety grounds and this profile held good in the trial. the concern i had that results might dissipate over the extended 6 month period seem to have been negated by the results which apparently indicated some level of improvement.so unless something very untoward occurs we should get fda approval at end of the day (usual caveats that nothing,absolutely nothing ,is nailed on).the real risk now lies in the execution.how well will it sell.it is very easy to get carried away with self promoting,sloganeering rhetoric such as "sex sells" ," this will fly off the shelves" etc. reality may well be different and the uncertainty until markets are actually tested explains, imo, the fairly muted reaction to the commercial deals so far announced. obviously i hope that actual sales are as good as we would wish, but i suspect the jury will require actual evidence of them before reaching its verdict.

thanks cong. appreciate that.